An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab

American Journal of Ophthalmology

Volumn 153, Issue 2, 2012, Pages

  Goldberg, Roger A ^a   Flynn, Harry W ^a   Isom, Ryan F ^a   Miller, Darlene ^a   Gonzalez, Serafin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

AGE RELATED MACULAR; AGED; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; DRUG CONTAMINATION; DRUG FORMULATION; EMERGENCY TREATMENT; ENDOPHTHALMITIS; EPIDEMIC; FEMALE; HUMAN; MALE; MEDICAL RECORD; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; STREPTOCOCCUS ENDOPHTHALMITIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS ORALIS; SYRINGE; TREATMENT OUTCOME; UNITED STATES; VITRECTOMY;

EID: 84862907626     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.11.035     Document Type: Article

References (16)

1. C.A. McCannel Meta-analysis of endophthalmitis following intravitreal injection of anti-VEGF agents: causative organisms and possible prevention strategies Retina 31 4 2011 654 661
2. A.A. Moshfeghi, P.J. Rosenfeld, H.W. Flynn Jr Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center Retina 31 4 2011 662 668
3. The CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
4. R.J. Brechner, P.J. Rosenfeld, J.D. Babish, S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare Fee-For-Service Part B claims file Am J Ophthalmol 151 5 2011 887 895
5. J.M. Miller, I.U. Scott, H.W. Flynn Jr, W.E. Smiddy, R.P. Corey, D. Miller Endophthalmitis caused by Streptococcus pneumoniae Am J Ophthalmol 138 2 2004 231 236 (Pubitemid 39037427)
6. A. Shaarawy, M.G. Grand, T.A. Meredith, H.E. Ibanez Persistent endophthalmitis after intravitreal antimicrobial therapy Ophthalmology 102 3 1995 382 387
7. C.C. Wykoff, H.W. Flynn Jr Endophthalmitis after intravitreal injection: prevention and management Retina 31 4 2011 633 635
8. B.A. Frost, M.A. Kainer Eye Opening: Are Compounding Drugs Causing Harm? Society for Healthcare Epidemiology of America 2011 Poster Presentation http://www.ismp.org/docs/paper4263.pdf Accessed: August 6, 2011
9. T. Wilemon Hospital gave tainted shots The Tennessean August 7, 2011 1B 5B
10. A. Pollack Five More Reports of Avastin Injections Causing Blindness The New York Times September 1, 2011 (online) http://www.nytimes.com/2011/09/02/ business/more-reports-of-avastin-causing-blindness.html?-r=1&hp Accessed: September 1, 2011
11. X. Sun, X. Xu, X. Zhang Counterfeit bevacizumab and endophthalmitis N Engl J Med 365 4 2011 378 379
12. J.-W. Cheng, R.-L. Wei Ranibizumab for age-related macular degeneration N Engl J Med 364 6 2011 582
13. S.H. Lee, S.J. Woo, K.H. Park Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab Eye 24 2 2010 226 232
14. Chapter 797 Pharmaceutical compoundingsterile preparations Revision Bulletin, The United States Pharmacopeia 2008 The United States Pharmacopeial Convention Rockville, MD 1 61
15. R.M. Rich, P.J. Rosenfeld, C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 2006 495 511 (Pubitemid 44620390)
16. C. Stucki, A.M. Sautter, J. Favet, P. Bonnabry Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulation on end-product quality Am J Health Syst Pharm 66 22 2009 2032 2036